Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial

Depression and Anxiety

Volumn 26, Issue 7, 2009, Pages 607-611

  Akhondzadeh, Shahin ^a   Jafari, Sara ^a   Raisi, Firoozeh ^a   Nasehi, Abbas Ali ^a   Ghoreishi, Aboulfazl ^b   Salehi, Bahman ^c   Mohebbi Rasa, Soodeh ^a   Raznahan, Maedeh ^a   Kamalipour, Abbas ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clinical trial; COX 2 inhibitor; Fluoxetine; Major depression

Indexed keywords

CELECOXIB; FLUOXETINE; PLACEBO;

ADJUVANT THERAPY; ADULT; ANXIETY DISORDER; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; EVENING DOSAGE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR DEPRESSION; MALE; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SIDE EFFECT; STOMACH PAIN; SWEATING; TREATMENT DURATION; TREMOR;

ADULT; CYCLOOXYGENASE 2 INHIBITORS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DINOPROSTONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZOLES; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SULFONAMIDES; YOUNG ADULT;

EID: 67650083320     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20589     Document Type: Article

References (28)

1. Sen S, Sanacora G. Major depression: emerging therapeutics. Mt Sinai J Med 2008;75:204-225.
2. Belmaker RH. The future of depression psychopharmacology. CNS Spectr 2008;13:682-687.
3. Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 2009;6:53-77.
4. Schatzberg AF. Achieving remission and favorable outcomes in patients with depression/anxiety and substance use disorders. CNS Spectr 2008;13:10-12.
5. Trivedi MH. Treating depression to full remission. J Clin Psychiatry 2009;70:e01.
6. Mendlewicz J. Towards achieving remission in the treatment of depression. Dialogues Clin Neurosci 2008;10:371-375.
7. Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22: 1-33. (Pubitemid 28096427)
8. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683-694. (Pubitemid 30249643)
9. Linnoila M, Whorton R, Rubinow DR, et al. CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 1983;40:405-406.
10. Ohishi K, Ueno R, Nishino S, et al. Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 1988;23:326-334. (Pubitemid 18043535)
11. Frommberger UH, Bauer J, Haselbauer P, et al. Interleukin-6- (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997;247:228-233. (Pubitemid 27399827)
12. Maes M, Bosmans E, De Jongh R, et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853-858. (Pubitemid 27494150)
13. Yermakova A, O'Banion MK. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 200;6:1755-1776. (Pubitemid 30944395)
14. Collantes-Estevez E, Fernandez-Perez C. Improved control of osteoarthritis pain and self-reported health status in nonresponders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr Med Res Opin 2003;19:402-410. (Pubitemid 36994443)
15. Guo JY, Li CY, Ruan YP, et al. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009; in press.
16. Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, addon pilot study to reboxetine. Mol Psychiatry 2006;11:680-684. (Pubitemid 43989814)
17. Nery FG, Monkul ES, Hatch JP, et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 2008;23:87-94. (Pubitemid 351359580)
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000.
19. Hamilton M. A rating scale for depression. J Neuro Neurosurg Psychiatry 1960;3:62-66.
20. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects; 2000. Available at: http://www.wma.net.
21. Andrews G. Reducing the burden of depression. Can J Psychiatry 2008;53:420-427.
22. Richelson E. Pharmacology of antidepressants-characteristic of the ideal drug. Mayo Clin Proceed 1994;69:1069-1081.
23. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo controlled trial. Schizophr Res 2007;90:179-185. (Pubitemid 46177578)
24. Müller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharmaceut Design 2008;14:1452-1465. (Pubitemid 351982552)
25. Simon NM, McNamara K, Chow CW, et al. A detailed examination of cytokine abnormalities in major depressive disorder. Eur Neuropsychopharmacol 2008;18:230-233.
26. Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009;24:65-75.
27. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-741.
28. Spektor G, Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk-where are we now? Nat Clin Pract Cardiovasc Med 2005;2:290-300.